文献速递消化系统肿瘤

纳米抗体工程化外泌体递送miR-204-5p靶向治疗结直肠癌的实验研究

[Targeted therapy for colorectal cancer through miR-204-5p delivered by nanobody-engineered exosomes: an experimental study].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

本研究制备了负载miR-204-5p的EGFR特异性纳米抗体7D12工程化外泌体7D12-hExo(204),并在体外和裸鼠移植瘤模型中评估其抗肿瘤效果。结果显示7D12-hExo(204)可靶向EGFR+的HCT116细胞,抑制其增殖、侵袭和迁移并促进凋亡,在裸鼠体内抑瘤率达82.8%且安全性良好。

要点

  • 7D12-hExo粒径(116.8±36.8)nm,电位约-10 mV,与未修饰hExo无显著变化。
  • 7D12-hExo对EGFR+ HCT116细胞荧光强度141.0±6.6,高于hExo组48.4±3.9(P<0.05)。
  • 7D12-hExo(204)体外抑制HCT116增殖侵袭迁移并促凋亡,裸鼠抑瘤率82.8%。

核心结论

  • 成功制备纳米抗体7D12修饰的天然载有miR-204-5p的外泌体,可高效递送miR-204-5p进入EGFR+结直肠癌细胞,发挥良好抗肿瘤效应并显示良好安全性。

研究设计与样本

  • 实验研究:利用稳定表达miR-204-5p的HEK293T细胞生产hExo,经糖代谢工程结合生物正交反应用纳米抗体7D12修饰获得7D12-hExo(204)。
  • 采用Western blot、电镜、动态光散射表征,免疫荧光和RT-qPCR评估靶向性,细胞生长曲线、平板克隆、Transwell、凋亡分析评估体外活性。
  • 通过结直肠癌裸鼠异种移植瘤模型评估体内抗肿瘤活性及安全性。

主要发现

  • 7D12-hExo粒径(116.8±36.8)nm,电位约-10 mV,与未修饰hExo相比均无明显变化。
  • EGFR+ HCT116细胞中hExo组、7D12-hExo组和7D12+7D12-hExo组荧光强度分别为48.4±3.9、141.0±6.6和38.7±3.2;7D12-hExo组较hExo组增强(P<0.05),7D12+7D12-hExo组较7D12-hExo组降低(P<0.05)。
  • EGFR- SW620细胞对hExo和7D12-hExo的摄取无明显差异。
  • hExo(204)组HCT116细胞克隆数(215.0±14.0)个、侵袭数(862.3±61.4)个、迁移数(1197.0±36.7)个、凋亡率(14.1±1.4)%;7D12-hExo(204)组分别为(65.0±15.1)个、(232.0±27.9)个、(725.7±32.7)个和(29.3±1.0)%;7D12-hExo(204)抑制增殖、侵袭和迁移(均P<0.05),促进凋亡(P<0.05)。
  • 裸鼠实验中7D12-hExo(204)显著抑制HCT116细胞移植瘤生长,抑瘤率82.8%,小鼠体重无明显变化,心、肝、脾、肺、肾组织HE染色未显示异常。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To develop an EGFR-targeting nanobody engineered exosome drug delivery system and evaluate its antitumor efficacy for colorectal cancer. Methods: The HEK293T cell line stably expressing the pan-cancer inhibitor miR-204-5p, previously established by our group, was selected as a tool cell line to prepare miR-204-5p-enriched exosomes. Using metabolic glycoengineering combined with bioorthogonal reaction strategy, these exosomes were modified with the EGFR-specific nanobody 7D12. Western blot, electron microscopy, and dynamic light scattering were used to characterize the engineered exosomes. The tumor target potential of engineered exosomes was evaluated using immunofluorescence and RT-qPCR. The in vitro anti-tumor activities of engineered exosomes were evaluated using cell growth curves, colony formation, Transwell, and apoptosis analyses. The in vivo anti-tumor activity and safety of engineered exosomes were evaluated using a nude mouse xenograft tumor model. Results: The particle size of 7D12-hExo was (116.8±36.8) nm, with a potential of around -10 mV, and there was no significant change compared with the unmodified hExo. Immunofluorescence assay showed that the fluorescence intensity of the hExo group, 7D12-hExo group, and 7D12+7D12-hExo group were 48.4±3.9, 141.0±6.6, and 38.7±3.2 in EGFR+ HCT116 cells, respectively. Compared with the hExo group, the fluorescence intensity of HCT116 cells in the 7D12-hExo group was significantly enhanced (P<0.05). Compared with the 7D12-hExo group, the fluorescence intensity in HCT116 cells in the 7D12+7D12-hExo group was significantly decreased (P<0.05). However, there was no significant difference in the uptake of hExo and 7D12-hExo in EGFR- SW620 colorectal cancer cells. The number of cell clones, invasion, and migration of HCT116 cells in the hExo (204) group was 215.0±14.0, 862.3±61.4, and 1 197.0 ± 36.7, respectively, with an apoptosis rate of (14.1±1.4)%. The number of cell clones, invasion, and migration of HCT116 cells in the 7D12-hExo (204) group was (65.0±15.1), (232.0±27.9), (725.7±32.7), respectively, with an apoptosis rate of (29.3±1.0)%. The 7D12-hExo (204) significantly inhibited the proliferation, invasion, and migration ability of HCT116 cells (P<0.05), resulting in promoting the apoptosis of HCT116 cells (P<0.05). Nude mouse experiments showed that 7D12-hExo (204) significantly inhibited the growth of tumors transplanted with HCT116 cells, with the inhibition rate being 82.8%. However, there was no significant change in mouse weight, and H&E staining of major organs such as heart, liver, spleen, lung, and kidney did not show any abnormalities. Conclusion: Naturally miR-204-5p-loaded exosomes were successfully modified with nanobody 7D12, which can efficiently deliver miR-204-5p into EGFR+ tumor cells, thereby exerting good anti-tumor therapeutic effects. 目的: 制备表皮生长因子(EGFR)特异性纳米抗体工程化的外泌体(Exo)载药体系并评估其靶向治疗结直肠癌的效果。 方法: 利用稳定表达泛癌抑制因子miR-204-5p的细胞系HEK293T,生产富含miR-204-5p的人源外泌体(hExo)。再利用糖代谢工程结合生物正交反应策略,对这些Exo进行抗EGFR纳米抗体7D12修饰,获得载有miR-204-5p的工程化Exo 7D12-hExo(204),采用Western blot、电镜、动态光散射等技术对其进行表征,采用免疫荧光和实时荧光定量聚合酶链反应评估7D12-hExo(204)的结直肠癌靶向性,采用细胞生长曲线、平板克隆、Transwell实验、凋亡分析评估了7D12-hExo(204)的体外抗肿瘤活性,通过结直肠癌裸鼠异种移植瘤模型评估7D12-hExo(204)的体内抗肿瘤活性及安全性。 结果: 7D12-hExo的粒径为(116.8±36.8)nm,电位在-10 mV左右,与未修饰的hExo相比,均无明显变化。免疫荧光法检测结果显示,对于EGFR+的HCT116细胞,hExo组、7D12-hExo组和7D12+7D12-hExo组的荧光强度分别为48.4±3.9、141.0±6.6和38.7±3.2,与hExo组相比,7D12-hExo组HCT116细胞中荧光强度增强(P<0.05);与7D12-hExo组相比,7D12+7D12-hExo组HCT116细胞中荧光强度降低(P<0.05)。而EGFR-的SW620结直肠癌细胞对hExo和7D12-hExo的摄取无明显差异。hExo(204)组HCT116细胞克隆数为(215.0±14.0)个,细胞侵袭数为(862.3±61.4)个,细胞迁移数为(1 197.0±36.7)个,凋亡率为(14.1±1.4)%,7D12-hExo(204)组分别为(65.0±15.1)个、(232.0±27.9)个、(725.7±32.7)个和(29.3±1.0)%,7D12-hExo(204)抑制了HCT116细胞的增殖、侵袭和迁移能力(均P<0.05),而促进了HCT116细胞凋亡(P<0.05)。裸鼠实验显示,7D12-hExo(204)能显著抑制HCT116细胞移植瘤的生长,抑瘤率达82.8%,但小鼠体重未发生明显变化,心、肝、脾、肺、肾等主要器官的组织HE染色也未显示异常。 结论: 成功制备了纳米抗体7D12修饰的天然载有miR-204-5p的Exo,可高效递送miR-204-5p进入EGFR+ 结直肠癌细胞,发挥良好的抗肿瘤效应,同时显示出良好的安全性。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gong L, Tian L, Li YC, et al. [Targeted therapy for colorectal cancer through miR-204-5p delivered by nanobody-engineered exosomes: an experimental study]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40375589. doi:10.3760/cma.j.cn112152-20231024-00211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。